Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of KL-6 as a Serum Biomarker in the Clinical Diagnosis of Interstitial Lung Diseases (ILD) in China

NCT02197364 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT02197364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02197364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of KL-6 as a Serum Biomarker in the Clinical Diagnosis of Interstitial Lung Diseases (ILD) in China
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Observational
Overall status
Completed
Start date
December 31, 2013
Completion date
May 31, 2014
Enrollment
1,190 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease